Literature DB >> 20176816

Esmolol cardioplegia: the cellular mechanism of diastolic arrest.

Hazem B Fallouh1, Sonya C Bardswell, Linda M McLatchie, Michael J Shattock, David J Chambers, Jonathan C Kentish.   

Abstract

AIMS: Esmolol, an ultra-short-acting beta-blocker, acts as a cardioplegic agent at millimolar concentrations. We investigated the mechanism by which esmolol induces diastolic ventricular arrest. METHODS AND
RESULTS: In unpaced Langendorff-perfused rat hearts, esmolol (0.03-3 mmol/L) had a profound negative inotropic effect resulting in diastolic arrest at 1 mmol/L and above. This inhibition of contraction was maintained during ventricular pacing. At 3 mmol/L, esmolol also abolished action potential conduction. To determine the cellular mechanism for the negative inotropism, we measured contraction (sarcomere shortening) and the calcium transient (fura-2 fluorescence ratio; Ca(tr)) in electrically-stimulated rat ventricular myocytes at 23 and 34 degrees C. The decrease in contraction (by 72% at 23 degrees C, from 0.16 +/- 0.01 to 0.04 +/- 0.01 microm, P < 0.001) was similar to that of isolated hearts and was caused by a large decrease in Ca(tr) (from 0.13 +/- 0.02 to 0.07 +/- 0.02, P < 0.001). There was no additional effect on myofilament Ca(2+) sensitivity. Esmolol's effects on contraction and Ca(tr) were not shared or altered by the beta-blocker, atenolol (1 mmol/L). Sarcoplasmic reticulum inhibition with thapsigargin did not alter the inhibitory effects of esmolol. Whole-cell voltage-clamp experiments revealed that esmolol inhibited the L-type calcium current (I(Ca,L)) and the fast sodium current (I(Na)), with IC(50) values of 0.45 +/- 0.05 and 0.17 +/- 0.025 mmol/L, respectively.
CONCLUSION: Esmolol at millimolar concentrations causes diastolic ventricular arrest by two mechanisms: at 1 mmol/L (and below), the pronounced negative inotropic effect is due largely to inhibition of L-type Ca(2+) channels; additionally, higher concentrations prevent action potential conduction, probably due to the inhibition of fast Na(+) channels.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20176816     DOI: 10.1093/cvr/cvq058

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  6 in total

1.  Myocardial protection in cardiac surgery: a historical review from the beginning to the current topics.

Authors:  Hiroshi Yamamoto; Fumio Yamamoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-07-23

Review 2.  Clinical pharmacokinetics and therapeutic efficacy of esmolol.

Authors:  Donald B Wiest; Jason S Haney
Journal:  Clin Pharmacokinet       Date:  2012-06-01       Impact factor: 6.447

3.  Effect of short-acting beta blocker on the cardiac recovery after cardiopulmonary bypass.

Authors:  Jie Sun; Zhengnian Ding; Yanning Qian
Journal:  J Cardiothorac Surg       Date:  2011-08-19       Impact factor: 1.637

4.  Myocardial energy metabolism and ultrastructure with polarizing and depolarizing cardioplegia in a porcine model.

Authors:  Terje Aass; Lodve Stangeland; David J Chambers; Seth Hallström; Christine Rossmann; Bruno K Podesser; Malte Urban; Knut Nesheim; Rune Haaverstad; Knut Matre; Ketil Grong
Journal:  Eur J Cardiothorac Surg       Date:  2017-07-01       Impact factor: 4.191

5.  Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol.

Authors:  Günther Krumpl; Ivan Ulč; Michaela Trebs; Juri Hodisch; Pavla Kadlecová; Bernhard Husch
Journal:  Cureus       Date:  2020-12-22

6.  Myocardial function after polarizing versus depolarizing cardiac arrest with blood cardioplegia in a porcine model of cardiopulmonary bypass.

Authors:  Terje Aass; Lodve Stangeland; Christian Arvei Moen; Pirjo-Riitta Salminen; Geir Olav Dahle; David J Chambers; Thomais Markou; Finn Eliassen; Malte Urban; Rune Haaverstad; Knut Matre; Ketil Grong
Journal:  Eur J Cardiothorac Surg       Date:  2016-02-02       Impact factor: 4.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.